Free Trial
NASDAQ:IRTC

iRhythm Technologies Q2 2025 Earnings Report

iRhythm Technologies logo
$136.24 +0.48 (+0.35%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$136.28 +0.04 (+0.03%)
As of 07/18/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iRhythm Technologies EPS Results

Actual EPS
N/A
Consensus EPS
-$0.53
Beat/Miss
N/A
One Year Ago EPS
N/A

iRhythm Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$173.94 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

iRhythm Technologies Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 31, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

iRhythm Technologies Earnings Headlines

Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
See More iRhythm Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iRhythm Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iRhythm Technologies and other key companies, straight to your email.

About iRhythm Technologies

iRhythm Technologies (NASDAQ:IRTC), Inc. is a medical technology company specializing in cardiac arrhythmia diagnostics through proprietary wearable biosensor devices and cloud-based analytics. Its flagship offering, the Zio patch, is a single-use adhesive patch designed to continuously monitor heart rhythm for up to 14 days. Data collected by the device is transmitted to a secure cloud platform where advanced algorithms analyze the recordings to detect irregular heartbeats and generate detailed reports for clinicians.

In addition to the Zio patch, iRhythm provides physician-supported diagnostic services that combine automated signal processing with expert human review. Reports identify occurrences of atrial fibrillation, bradycardia, pauses, tachycardia and other arrhythmic events, helping physicians make informed decisions on patient management. The company partners with hospitals, outpatient centers and physician practices, as well as payers, to support remote cardiac monitoring and streamlined reporting workflows.

Founded in 2006 and headquartered in San Francisco, California, iRhythm initially commercialized its Zio service following FDA clearance in 2011. Since then, the company has expanded its footprint beyond the United States into select markets across Europe and the Asia-Pacific region. Under the leadership of CEO Kevin King and a management team with expertise in cardiovascular diagnostics and digital health, iRhythm continues to invest in research collaborations and product enhancements aimed at improving arrhythmia detection and broadening access to remote cardiac monitoring solutions.

View iRhythm Technologies Profile

More Earnings Resources from MarketBeat